Since HMGB1 was further shown to promote expression of SARS-CoV-2 entry receptor ACE2 in alveolar epithelial cells, targeting HMGB1 by pharmacological inhibition might be a potential treatment option for COVID-19 patients. Here, HMGB1 is linked to COVID-19.